

Contents

Part I MicroRNA	1
An Overview of MicroRNA	3
E. Wang	
MicroRNAs and Their Potential	17
M. Abdellatif	
miRNAs and Their Emerging Role in Cardiac Hypertrophy	35
T.E. Callis, M. Tatsuguchi, and D.-Z. Wang	
MicroRNAs and the Control of Heart Pathophysiology	53
D. Catalucci, M.V.G. Latronico, and G. Condorelli	
MicroRNA Systems Biology	69
E. Wang	
Part II RNA Interference	87
Targeting Viral Heart Disease by RNA Interference	89
S. Merl and R. Wessely	
Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications	109
V. Pekarik	
RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders: Status and Challenges	131
W. Poller, L. Suckau, S. Pinkert, and H. Fechner	
Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors	167
O.J. Müller and H.A. Katus	

Part III Ribozymes	183
Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases	185
G. Grassi and M. Grassi	
Applications of Ribozymes and Pyrrole–Imidazole Polyamides for Cardiovascular and Renal Diseases	209
E.-H. Yao and N. Fukuda	
Part IV Noncoding, Aptamer and Antisense RNAs	233
Noncoding RNAs in Human Diseases	235
M. Szymański and J. Barciszewski	
Aptamers and siRNAs in Cardiovascular Disease	255
C.M. Blake, S. Oney, S.M. Nimjee, and B.A. Sullenger	
Nucleic Acid Aptamers for Cardiovascular Therapeutics	289
P.S. Pendergrast, K.M. Thompson, and R.G. Schaub	
NFκB Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases	299
H. Nakagami, M.K. Osako, N. Tomita, and R. Morishita	
Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions	311
N. Kipshidze	
Toxic RNA in Pathogenesis of Human Neuromuscular Disorders	325
D. Napierala and M. Napierala	
Index	355